5662 Journal of Medicinal Chemistry, 2008, Vol. 51, No. 18
Dawson et al.
(14) Benoit, G.; Cooney, A.; Giquere, V.; Ingraham, H.; Lazar, M.; Mucat,
G.; Perlmann, T.; Renaud, J. P.; Schwabe, J.; Sladek, F.; Tsai, M. J.;
Laudet, V. International union of pharmacology. LXVI. Orphan nuclear
receptors. Pharmacol. ReV. 200658, 798–836.
(15) Seol, W.; Choi, H. S.; Moore, D. D. An orphan nuclear hormone
receptor that lacks a DNA binding domain and heterodimerizes with
other receptors. Science 1996, 272, 1336–1339.
(16) Wurtz, J. M.; Bourguet, W.; Renaud, J. P.; Vivat, V.; Chambon, P.;
Moras, D.; Gronemeyer, H. A canonical structure for the ligand-
binding domain of nuclear receptors. Nat. Struct. Biol. 1996, 3, 87–
94.
(17) Park, Y.-Y.; Kim, H.-J.; Kim, J.-Y.; Kim, M.-Y.; Song, K.-H.; Park,
K.-C.; Yu, K.-Y.; Shong, M.; Kim, K.-H.; Choi, S. Differential role
of the loop region between helices H6 and H7 within the orphan
nuclear receptors small heterodimer partner and DAX-1. Mol. Endo-
crinol. 2004, 18, 1082–1095.
(18) Iyer, A. K.; Zhang, Y.-H.; McCabe, E. R. B. Dosage-sensitive sex
reversal adrenal hypoplasia congenital critical region on the X
chromosome, gene 1 (DAX1) (NR0B1) and small heterodimer partner
(SHP) (NR0B2) form homodimers individually, as well as DAX1-
SHP heterodimers. Mol. Endocrinol. 2006, 20, 2326–2342.
(19) Lee, Y.-S.; Chanda, D.; Sim, J.; Park, Y.-Y.; Choi, H.-S. Structure
and function of the atypical orphan nuclear receptor small heterodimer
partner. Int. ReV. Cytol. 2007, 261, 117–158.
(36) Zhu, X. Z.; Yu, Y. Z.; Fang, Y. M.; Liang, Y.; Lu, Q. H.; Xu, R. Z.
[Overexpression of Shp-2 is associated with the unlimited growth and
apoptosis resistance of p210 bcr-al-mediated chronic myeloid leuke-
mia]. Zhonghua Yi Xue Za Zhi 200585, 1903–1906.
(37) Scheiner, S.; Kar, T.; Pattanayak, J. Comparison of various types of
hydrogen bonds involving aromatic amino acids. J. Am. Chem. Soc.
2002, 124, 13257–13264.
(38) Kova´cs, A.; Varga, Z. Halogen acceptors in hydrogen bonding. Coord.
Chem. ReV. 2006, 250, 710–727.
(39) Rishi, A. K.; Zhang, L.; Boyanapalli, M.; Wali, A.; Mohammad, R. M.;
Yu, Y.; Fontana, J. A.; Hatfield, J. S.; Dawson, M. I.; Majumdar, A. P.;
Reichert, U. Identification and characterization of a cell cycle and
apoptosis regulatory protein-1 as a novel mediator of apoptosis
signaling by retinoid CD437. J. Biol. Chem. 2003, 278, 33422–33435.
(40) Lu, X. P.; Fanjul, A.; Picard, N.; Shroot, B.; Pfahl, M. A selective
retinoid with high activity against an androgen-resistant prostate cancer
cell type. Int. J. Cancer 1999, 80, 272–278.
(41) Ortiz, M. A.; Lopez-Hernandez, F. J.; Bayon, Y.; Pfahl, M.; Piedrafita,
F. J. Retinoid-related molecules induce cytochrome c release and
apoptosis through activation of c-Jun NH2-terminal kinase/p38 mito-
gen-activated protein kinases. Cancer Res. 2001, 61, 8504–8512.
(42) Pisano, C.; Merlini, L.; Penco, S.; Carminati, P.; Zunino, F. Cellular
and pharmacological bases of the antitumor activity of a novel
adamantyl retinoid, ST1926. J. Chemother. 2004, (Suppl. 4), 74–76.
(43) Cincinelli, R.; Dallavalle, S.; Nannei, R.; Carella, S.; De Zani, D.;
Merlini, L.; Penco, S.; Garattini, E.; Giannini, G.; Pisano, C.; Vesci,
L.; Carminati, P.; Zuco, V.; Zanchi, C.; Zunino, F. Synthesis and
structure-activity relationships of a new series of retinoid-related
biphenyl-4-ylacrylic acids endowed with antiproliferative and proapo-
ptotic activity. J. Med. Chem. 2005, 48, 4931–4946.
(44) Cincinelli, R.; Dallavalle, S.; Merlini, L.; Penco, S.; Pisano, C.;
Carminati, P.; Giannini, G.; Vesci, L.; Gaetano, C.; Illy, B.; Zuco,
V.; Supino, R.; Zunino, F. A novel atypical retinoid endowed with
proapoptotic and antitumor activity. J. Med. Chem. 2003, 46, 909–
912.
(45) Cincinelli, R.; Dallavalle, S.; Nannei, R.; Merlini, L.; Penco, S.;
Giannini, G.; Pisano, C.; Vesci, L.; Ferrara, F. F.; Zuco, V.; Zanchi,
C.; Zunino, F. Synthesis and structure-activity relationships of new
antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic
acids. Bioorg. Med. Chem. 2007, 15, 4863–4875.
(46) Pisano, C.; Vesci, L.; Fodera`, R.; Ferrara, F. F.; Rossi, C.; De Cesare,
M.; Zuco, V.; Pratesi, G.; Supino, R.; Zunino, F. Antitumor activity
of the retinoid-related molecules (E)-3-(4′-hydroxy-3′-adamantylbi-
phenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydrox-
yphenyl]-2-naphthalenecarboxylic acid (CD437) in F9 teratocarcinoma:
Role of retinoic acid receptor γ and retinoid-independent pathways.
Mol. Pharmacol. 2006, 70, 909–924.
(47) Amin, A. R. M.; Thakur, V. S.; Paul, R. K.; Feng, G. S.; Qu, C.-K.;
Mukhtar, H.; Agarwal, M. L. SHP-2 tyrosine phosphatase inhibits p73-
dependent apoptosis and expression of a subset of p53 target genes
induced by EGCG. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 5419–
5424.
(48) Yart, A.; Mayeux, P.; Raynal, P. Gab1, SHP-2 and other novel
regulators of Ras: Targets for anticancer drug discovery. Curr. Cancer
Drug Targets 2003, 3, 177–192.
(49) Van der Burgt, I. Noonan syndrome. Orphanet J. Rare Dis. 2007, 2,
4.
(50) Bocchinfuso, G.; Stella, L.; Martinelli, S.; Flex, E.; Carta, C.;
Pantaleoni, F.; Pispisa, B.; Venanzi, M.; Tartaglia, M.; Palleschi, A.
Structural and functional effects of disease-causing amino acid
substitutions affecting residues Ala72 and Glu76 of the protein tyrosine
phosphatase SHP-2. Proteins 2007, 66, 963–974.
(51) Uehara, T.; Suzuki, K.; Yamanaka, H.; Kizaki, T.; Sakurai, T.;
Ishibashi, Y.; Ishida, H.; Ohno, H. SHP-2 positively regulates
adipogenic differentiation in 3T3-L1 cells. Int. J. Mol. Med. 2007,
19, 895–900.
(52) Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and
testing of the OPLS all-atom force field on conformational energetics
and proprieties of organic liquids. J. Am. Chem. Soc. 1996, 118,
11225–11236.
(53) Chang, G.; Guida, W. C.; Still, W. C. An internal coordinate Monte-
Carlo method for searching conformational space. J. Am. Chem. Soc.
1989, 111, 4379–4386.
(20) Båvner, A.; Johansson, L.; Toresson, G.; Gustafsson, J.-Å.; Treuter,
E. A transcriptional inhibitor targeted by the atypical orphan nuclear
receptor SHP. EMBO Rep. 2002, 3, 478–484.
(21) Gobinet, J.; Carascossa, S.; Cavailles, V.; Vignon, F.; Nicolas, J. C.;
Jalaguier, S. SHP represses transcriptional activity via recruitment of
histone deacetylases. Biochemistry 2005, 44, 6312–6320.
(22) Ortlund, E. A.; Lee, Y.; Solomon, I. H.; Hager, J. M.; Safi, R.; Choi,
Y.; Guan, Z.; Tripathy, A.; Raetz, C. R.; McDonnell, D. P.; Moore,
D. D. Modulation of human nuclear receptor LRH-1 activity by
phospholipids and SHP. Nat. Struct. Mol. Biol. 2005, 12, 357–363.
(23) Egea, P. F.; Mitschler, A.; Rochel, N.; Ruff, M.; Chambon, P.; Moras,
D. Crystal structure of the human RXRR ligand-binding domain bound
to its natural ligand: 9-cis retinoic acid. EMBO J. 2000, 19, 2592–
2601.
(24) Egea, P. F.; Mitschler, A.; Moras, D. Molecular recognition of agonist
ligands by RXRs. Mol. Endocrinol. 2002, 16, 987–997.
(25) Jones, G.; Jones, D.; Teal, P.; Sapa, A.; Wozniak, M. The retinoid-X
receptor ortholog, ultraspiracle, binds with nanomolar affinity to an
endogenous morphogenetic ligand. FEBS J. 2006, 273, 4983–4996.
(26) Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions
of organoboron compounds. Chem. ReV. 1995, 95, 2457–2483.
(27) Olifirov, D. I.; Koshchii, V. A.; Kozlikovskii, Ya. B. Reaction of
1-hydroxyadamantane with aromatic amines in the presence of ortho-
alkylation catalysts. Zh. Org. Khim. 1992, 28, 182–187.
(28) Krishna Mohan, K. V. V.; Narender, N.; Srinivasu, P.; Kulkarni, S. J.;
Raghavan, K. V. Novel bromination method for anilines and anisoles
using NH4Br/H2O2 in CH3COOH. Synth. Commun. 2004, 34, 2143–
2152.
(29) Holzapfel, C. W.; Dwyer, C. Still and Suzuki cross-coupling reactions
of o-nitrophenyl triflates: A versatile route to a variety of heterocycles.
Heterocycles 1998, 48, 1513–1518.
(30) Ailprandi, B.; Cacace, F.; Fornarini, S. Gas phase alkylation of
halobenzenes by free isopropyl cations. Tetrahedron 1987, 43, 2831–
2841.
(31) Bertha, F.; Fetter, J.; Kajta´r-Peredy, M.; Lempert, K.; Czira, G. Simple
and condensed ꢀ-lactams, Part 31. Acid catalyzed ring closures and
ring transformations of some 3-aryloxy-4-oxoazetidine-2-carbalde-
hydes. Tetrahedron 1998, 54, 15227–15242.
(32) Van De Water, R. W.; Magdziak, D. J.; Chau, J. N.; Pettus, T. R. R.
New construction of ortho ring-alkylated phenols via generation and
reaction of assorted o-quinone methides. J. Am. Chem. Soc. 2000, 122,
6502–6503.
(33) Gieseler, F.; Bauer, E.; Nuessler, V.; Clark, V.; Valsamas, S. Molecular
effect of topoisomerase II inhibitors in AML cell lines: Correlation
of apoptosis with topoisomerase II activity but not with DNA damage.
Leukemia 1999, 13, 1859–1863.
(34) Amico, D.; Barbui, A. M.; Erba, E.; Rambaldi, A.; Introna, M.; Golay,
J. Differential response of human acute myeloid leukemia cell to
gemtuzumab ozogamicin in vitro: Role of Chk1 and Chk2 phosphop-
rylation and caspase 3. Blood 2003, 101, 4589–4597.
(54) Kolossva´ry, I.; Guida, W. C. Low Model Search. An efficient,
automated computational method for conformational analysis: Ap-
plication to cyclic and acyclic alkanes and cyclic peptides. J. Am.
Chem. Soc. 1996, 118, 5011–5019.
(35) Ju, M. Z.; Kapoor, K.; Newton, K.; Cheon, R. L.; Strong, L. C.; Koo,
J. S. Global detection of molecular changes reveals concurrent
alteration of several biological pathways in nonsmall cell lung cancer
cells. Mol. Genet. Genomics 2005, 274, 141–154.
JM800456K